Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNA Vaccination Against Neuroblastoma
NCT04049864Phase 1Unknown
- Sponsor
- Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
- Start
- Jan 2019
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in neuroblastoma, sponsored by Belarusian Research Center for Pediatric Oncology, Hematology and Immunology. Primary endpoints: Adverse Events at 3 months, Immune response to the vaccine at 14 weeks and 1 more. Status: unknown.
02
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT04049864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04049864.